Outlook Therapeutics (OTLK) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Outlook Therapeutics

NasdaqCM•Healthcare•Biotechnology

$0.64-0.03(-0.04%)Pre-market

Market Cap

$93.12M

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. Outlook Therapeutics, Inc. was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

How this company scores

WeakMetricSide Score: 26/100

Grade capped at D — Negative equity — the balance sheet is insolvent. Strongest: Balance Sheet & Red Flags (15/25); weakest: Profitability (0/25).

Profitability0/25

Growth5/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Interest easily coveredNet cash position

Grade capped at D

Negative equity — the balance sheet is insolvent.

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 1.8x5y range 1.8x – 1.8x

P/S · 49.4x5y range 26.1x – 545.8x

Currently below its 8-quarter median.

P/B · 533.5x5y range 107.1x – 1411.6x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $93.12M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $-1.16M
Q. Revenue: $8,700
TTM EBITDA: $-55.47M
TTM Op. Income: $-55.64M
Q. Op. Income: $-10.81M
TTM Net Income: $-61.12M
Q. Net Income: $-20.32M
EPS: $-0.15
Shares Out.: $136.74M

$-1.16M in TTM revenue declined 177.3% YoY, reaching $8,700 last quarter. TTM EBITDA of $-55.47M and TTM operating income of $-55.64M show growth is flowing through to the bottom line. However, net income is negative at $61.12M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 177% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: -95.0%
EBITDA Margin: -124096.8%
Op. Margin: -124255.3%
Net Margin: -233554.9%

Op. margin of -124255.3% is down 123209.1% YoY — costs are rising relative to revenue. Net margin at -233554.9% and gross margin of -95.0% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has fallen for 3 consecutive quarters — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: N/A
P/B Ratio: N/A

P/S of 0.0x and P/B of 0.0x.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $26.18M
Cash: $11.24M
Long-Term Debt: N/A
Book Value: $-10.39M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-21.01M
TTM Free Cash Flow: $-56.15M
FCF Margin: N/A
FCF / Net Income: 0.9

TTM FCF of $-56.15M on $-21.01M in operating cash flow. The FCF / Net Income ratio of 0.9x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 0% — a weakening trend.